Genmab
GMAB
211 hedge funds and large institutions have $1.89B invested in Genmab in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 99 increasing their positions, 54 reducing their positions, and 27 closing their positions.
644% more call options, than puts
Call options by funds: $6.93M | Put options by funds: $931K
83% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 54
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
0% more capital invested
Capital invested by funds: $1.89B → $1.89B (+$2.65M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less funds holding
Funds holding: 212 → 211 (-1)
5.26% less ownership
Funds ownership: 70.37% → 65.11% (-5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$18.8M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$7.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.12M |
| 4 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
+$4.97M |
| 5 |
Jane Street
New York
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$54M |
| 2 |
BlackRock
New York
|
-$37.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$21.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.3M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$15.6M |
GMAB Hedge Fund Activity: Q3 2021 in Review
211 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2021, worth a combined $1.89B — up 0.14% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new GMAB positions and 27 closed out — a net gain of 2 holders — while 99 added to existing stakes and 54 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $18.8M. The largest seller was Schroder Investment Management Group, cutting an estimated $54M.
- 211 institutional investors held Genmab (GMAB) as of Q3 2021, down from 212 in Q2 2021.
- Funds reported $1.89B of Genmab stock for Q3 2021, up 0.14% quarter-over-quarter.
- 29 funds opened new Genmab positions in Q3 2021 and 27 closed out, a net change of +2 holders.
- The largest Genmab buyer in Q3 2021 was Arrowstreet Capital, an estimated $18.8M added.
- The largest Genmab seller in Q3 2021 was Schroder Investment Management Group, an estimated $54M sold.
Based on aggregated 13F filings for Q3 2021.